Literature DB >> 7711487

Apathy: a treatable syndrome.

R S Marin1, B S Fogel, J Hawkins, J Duffy, B Krupp.   

Abstract

Apathy occurs frequently in neuropsychiatric disorders both as a symptom of other syndromes and as a syndrome per se. Histories are presented of patients with a syndrome of apathy who showed clinically significant, sustained benefit from pharmacological treatment. Etiologies included non-Alzheimer's frontal lobe dementia, cerebral infarction, intracranial hemorrhage, alcoholism, and traumatic brain injury. Agents included amantadine, amphetamine, bromocriptine, bupropion, methylphenidate, and selegiline. These histories support the suggestion that apathy is a discriminable dimension of behavior having its own pathophysiology and implications for psychiatric care. They raise the possibility of treatment for many patients previously thought untreatable. Studying the treatment of apathy may contribute to the clinical care and scientific understanding of neuropsychiatric disorders throughout the life span.

Entities:  

Mesh:

Year:  1995        PMID: 7711487     DOI: 10.1176/jnp.7.1.23

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  35 in total

Review 1.  REVIEW: Apathy diagnosis, assessment, and treatment in Alzheimer's disease.

Authors:  Philippe H Robert; Emmanuel Mulin; Patrick Malléa; Renaud David
Journal:  CNS Neurosci Ther       Date:  2010-10       Impact factor: 5.243

Review 2.  Are the available apathy measures reliable and valid? A review of the psychometric evidence.

Authors:  Diana E Clarke; Jean Y Ko; Emily A Kuhl; Robert van Reekum; Rocio Salvador; Robert S Marin
Journal:  J Psychosom Res       Date:  2010-03-31       Impact factor: 3.006

3.  Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system.

Authors:  Carlo Blundo; Carmela Gerace
Journal:  Neurol Sci       Date:  2015-01-21       Impact factor: 3.307

Review 4.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

Review 5.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

6.  Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection.

Authors:  Rujvi Kamat; Gregory G Brown; Khalima Bolden; Christine Fennema-Notestein; Sarah Archibald; Thomas D Marcotte; Scott L Letendre; Ronald J Ellis; Steven Paul Woods; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2014-10-02       Impact factor: 2.475

Review 7.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 8.  Mood disorders after TBI.

Authors:  Ricardo E Jorge; David B Arciniegas
Journal:  Psychiatr Clin North Am       Date:  2014-01-14

9.  Apathy after hip fracture: a potential target for intervention to improve functional outcomes.

Authors:  Eric J Lenze; Michael C Munin; Mary Amanda Dew; Robert S Marin; Meryl A Butters; Elizabeth R Skidmore; Ellen M Whyte; Amy Begley; Charles F Reynolds
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2009       Impact factor: 2.198

Review 10.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.